Frankfurt - Delayed Quote EUR

FSD PHARMA B (0K9.F)

0.4945 +0.0595 (+13.68%)
As of 1:46 PM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
19,570.1140
19,570.1140
27,429.6110
33,743.6600
30,601.2280
Operating Income
-19,570.1140
-19,570.1140
-27,429.6110
-33,743.6600
-30,601.2280
Net Non Operating Interest Income Expense
786.0640
786.0640
318.9130
-68.1120
-231.8900
Other Income Expense
553.4620
553.4620
407.0360
-126.1840
2,380.8860
Pretax Income
-18,230.5880
-18,230.5880
-26,703.6620
-33,937.9560
-28,452.2320
Net Income Common Stockholders
-17,902.1790
-17,902.1790
-23,606.8280
-35,285.4290
-31,799.7930
Diluted NI Available to Com Stockholders
-17,902.1790
-17,902.1790
-23,606.8280
-35,285.4290
-31,799.7930
Basic EPS
-0.46
-0.46
-0.61
-1.01
-2.64
Diluted EPS
-0.46
-0.46
-0.61
-1.01
-2.64
Basic Average Shares
39,588.6630
39,588.6630
38,732.3810
34,945.2100
12,043.9610
Diluted Average Shares
39,588.6630
39,588.6630
38,732.3810
34,945.2100
12,043.9610
Total Operating Income as Reported
-23,789.4980
-23,789.4980
-27,429.6110
-33,743.6600
-30,691.0880
Total Expenses
19,570.1140
19,570.1140
27,429.6110
33,743.6600
30,601.2280
Net Income from Continuing & Discontinued Operation
-17,902.1790
-17,902.1790
-23,606.8280
-35,285.4290
-31,799.7930
Normalized Income
-13,516.6260
-13,516.6260
-26,991.2450
-33,761.9800
-30,152.9540
Interest Income
786.3630
786.3630
367.7350
1.2920
3.6910
Interest Expense
0.2990
0.2990
48.8220
69.4040
235.5810
Net Interest Income
786.0640
786.0640
318.9130
-68.1120
-231.8900
EBIT
-18,230.2890
-18,230.2890
-26,654.8400
-33,868.5520
-28,216.6510
EBITDA
-15,723.9730
-15,723.9730
-22,117.4250
-29,823.0290
-24,316.1930
Reconciled Depreciation
2,506.3160
2,506.3160
4,534.5860
4,045.5230
3,900.4580
Net Income from Continuing Operation Net Minority Interest
-17,902.1790
-17,902.1790
-26,703.6620
-33,937.9560
-28,452.2320
Total Unusual Items Excluding Goodwill
-4,385.5530
-4,385.5530
287.5830
-175.9760
1,700.7220
Total Unusual Items
-4,385.5530
-4,385.5530
287.5830
-175.9760
1,700.7220
Normalized EBITDA
-11,338.4200
-11,338.4200
-22,405.0080
-29,647.0530
-26,016.9150
12/31/2020 - 11/20/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

FLGC Flora Growth Corp.
1.5450
-0.32%
 
RDHL RedHill Biopharma Ltd.
0.4100
-2.36%
 
AVDL Avadel Pharmaceuticals plc
16.96
-3.97%
 
ELAN Elanco Animal Health Incorporated
12.97
-2.55%
 
HLN Haleon plc
8.37
+0.18%
 
AQST Aquestive Therapeutics, Inc.
3.7900
-2.82%
 
CGC Canopy Growth Corporation
8.95
-0.22%